Effect of Intravenous Metoprolol Combining RIC on Myocardial Protection in STEMI Patients

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1206 participants.

Also called NCT03579914

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,206 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03579914
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03579914. Randomized; no masking; primary purpose treatment. Start 2017-11-28 (actual); primary completion 2020-08-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Intravenous Metoprolol Combining RIC on Myocardial Protection in STEMI Patients
Condition
Anterior Myocardial Infarction
Condition
Heart Failure
Intervention (Drug)
intravenous Placebo
Intervention (Drug)
Metoprolol Injectable Product
Intervention (Device)
Romote Ischemic Conditioning (RIC)
Intervention (Combination product)
Metoprolol & RIC
Lead sponsor
Harbin Medical University (class: other)
Collaborator
Beijing Chao Yang Hospital (class: other)

Record details

Record id
cardio:ct-nct03579914
Content hash
45e6830831d76bb887b91a60a3ac6656d69d39acd37aacc69ea5bc264bc6ec39